Abstract
Sulindac is a long-acting nonsteroidal anti-inflammatory drug (NSAID) widely used for the management of osteoarthritis, rheumatoid arthritis, ankylosing sponydlitis, and acute gouty arthritis. Reports of sulindac toxicity in the literature are rare. We report the case of a 22-year old male with a history of bipolar disorder who was brought to the emergency department after ingesting approximately 15 g of sulindac in a suicide attempt. He was found to have acute kidney injury and hyperbilirubinemia. Despite aggressive fluid resuscitation, his renal function progressively worsened requiring the initiation of hemodialysis. Ten days following ingestion of sulindac, he began to develop ischemic skin changes with a gangrenous appearance in his hands and feet. He continued to receive supportive treatment, and his acute kidney injury, hyperbillirubinemia, and ischemic skin necrosis eventually resolved. Clinicians should be aware of this long-acting NSAID and its ability to cause prolonged multisystem organ dysfunction.
Keywords: Clinoril, hepatotoxicity, nephrotoxicity, NSAID, overdose, sulindac.
Current Drug Safety
Title:Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose
Volume: 10 Issue: 2
Author(s): John L. Vaughn, Kejal V. Shah, Maroun M. Ghossein, William L. Meyer and Robert B. Kirkpatrick
Affiliation:
Keywords: Clinoril, hepatotoxicity, nephrotoxicity, NSAID, overdose, sulindac.
Abstract: Sulindac is a long-acting nonsteroidal anti-inflammatory drug (NSAID) widely used for the management of osteoarthritis, rheumatoid arthritis, ankylosing sponydlitis, and acute gouty arthritis. Reports of sulindac toxicity in the literature are rare. We report the case of a 22-year old male with a history of bipolar disorder who was brought to the emergency department after ingesting approximately 15 g of sulindac in a suicide attempt. He was found to have acute kidney injury and hyperbilirubinemia. Despite aggressive fluid resuscitation, his renal function progressively worsened requiring the initiation of hemodialysis. Ten days following ingestion of sulindac, he began to develop ischemic skin changes with a gangrenous appearance in his hands and feet. He continued to receive supportive treatment, and his acute kidney injury, hyperbillirubinemia, and ischemic skin necrosis eventually resolved. Clinicians should be aware of this long-acting NSAID and its ability to cause prolonged multisystem organ dysfunction.
Export Options
About this article
Cite this article as:
Vaughn L. John, Shah V. Kejal, Ghossein M. Maroun, Meyer L. William and Kirkpatrick B. Robert, Acute Kidney Injury, Hyperbilirubinemia, and Ischemic Skin Necrosis Due to Massive Sulindac Overdose, Current Drug Safety 2015; 10(2) . https://dx.doi.org/10.2174/157488631002150515150729
DOI https://dx.doi.org/10.2174/157488631002150515150729 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Meet Our Editorial Board Member:
Current Traditional Medicine Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure-Based Development of Antagonists for Chemokine Receptor CXCR4
Current Computer-Aided Drug Design Evaluation of Biochemical Properties of Digestive Lipolytic Enzymes from the Marine Snail (Hexaplex trunculus)
The Natural Products Journal TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Immunological Aspects of the Complex Regional Pain Syndrome (CRPS)
Current Pharmaceutical Design Sole Anti-inflammatory Immunomodulators: Innovative Drugs to Prevent and Treat Autoimmune Diseases and Proteopathies
Current Chinese Science Fibromyalgia: Mechanisms, Current Treatment and Animal Models
Current Pharmaceutical Biotechnology High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades
Current Pharmaceutical Design Preparation of Supramolecular Hydrogels Containing Poloxamers and Methyl-β-cyclodextrin
Letters in Drug Design & Discovery Osteoblast-n-Osteoclast: Making Headway to Osteoporosis Treatment
Current Drug Targets Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological and Pathological Responses
MicroRNA Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Current Drug Targets Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Traditional Chinese Medicine for Managing Inflammatory Pain of Arthritis with Herbal Medicines
Current Traditional Medicine